Drugs / TQC3927
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06711991 | Feb → Aug 2025 | chronic obstructive pulmonary disease | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06408285 | May → Aug 2024 | chronic obstructive pulmonary disease | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07633314 | Dec 2026 | chronic obstructive pulmonary disease | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQC3927 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06711991 ↗ |
| Action | Inhibit | “TQC3927 is a targeted inhibitor.” NCT06408285 ↗ |
| Route | Inhaled | “TQC3927 powder for inhalation” NCT06408285 ↗ |